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Rapidly proliferating cells promote glycolysis in aerobic conditions, to increase growth rate. 
Expression  of  specific  glycolytic  enzymes,  namely  pyruvate  kinase  m2  and  hexokinase  2, 
concurs to this metabolic adaptation, as their kinetics and intracellular localization favour 
biosynthetic  processes  required  for  cell  proliferation.  Intracellular  factors  regulating  their 
selective expression remain largely unknown. Here we show that the peroxisome proliferator-
activated  receptor  gamma  transcription  factor  and  nuclear  hormone  receptor  contributes 
to selective pyruvate kinase m2 and hexokinase 2 gene expression in PTEN-null fatty liver. 
Peroxisome proliferator-activated receptor gamma expression, liver steatosis, shift to aerobic 
glycolysis and tumorigenesis are under the control of the Akt2 kinase in PTEN-null mouse livers. 
Peroxisome proliferator-activated receptor gamma binds to hexokinase 2 and pyruvate kinase 
m  promoters  to  activate  transcription.  In  vivo  rescue  of  peroxisome  proliferator-activated 
receptor gamma activity causes liver steatosis, hypertrophy and hyperplasia. our data suggest 
that  therapies  with  the  insulin-sensitizing  agents  and  peroxisome  proliferator-activated 
receptor gamma agonists, thiazolidinediones, may have opposite outcomes depending on the 
nutritional or genetic origins of liver steatosis. 
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G
lycolysis  generates  energy  and  intermediates  for  macro-
molecule  biosynthesis.  Hence  the  growth  factors,  ana-
bolic hormones and oncogenic events perfected molecular   
mechanisms  to  upregulate  glycolytic  enzyme  activities  and  gene 
expression1.  The  phosphatidylinositol-3-kinase  (PI3K)  pathway, 
a  master  regulator  of  cell  growth,  proliferation  and  metabolism 
in response to insulin, growth factors and oncogenic insults, is a 
potent stimulator of glycolysis by acting on different levels, from 
the upregulation of glucose uptake at the membrane, to the post-
translational modifications of glycolytic enzymes, to the induction 
of  glycolytic  gene  expression2.  In  the  nucleus,  the  transcription 
factor c-Myc, encoded by the MYC oncogene, directly binds and 
activates the majority of glycolytic gene promoters3. In addition, 
the hypoxia-inducible factor 1 (HIF-1), which can accumulate in 
cells as a consequence of inactivating mutations in the Von Hippel– 
Lindau (VHL) tumour suppressor gene, cooperates with c-Myc on 
the transcriptional activity of the glycolytic gene promoters4. Further   
complexity comes from the existence of multiple isozymes catalys-
ing specific reactions in glycolysis. For instance, four hexokinases 
(HK1-4) catalyse the first step of glycolysis, that is, the phosphoryla-
tion of glucose, while four pyruvate kinases (PKM1, PKM2, PKL, 
PKR) catalyse the last step of glycolysis, that is, the final conver-
sion of phosphoenolpyruvate to pyruvate. These isozymes display 
differential tissue distribution and confer specific kinetic and regu-
latory properties to the glycolytic flux5–7. However the molecular 
mechanisms  favouring  selective  expression  of  specific  isozymes   
remain mysterious.
Pyruvate, the end product of glycolysis, can be reduced to lactate 
in the cytosol during anaerobic conditions or enter the mitochondria 
to be further oxidized during aerobic respiration. In rapidly dividing 
cells, lactate production is also observed under normal oxygen con-
ditions, a phenomenon called aerobic glycolysis or Warburg effect, 
which may provide a growth advantage by producing carbon inter-
mediates as building blocks for cellular components1. Among the gly-
colytic isozymes, the expression of hexokinase 2 (HK2) and the M2 
isoform of pyruvate kinase (PKM2) may particularly favour aerobic 
glycolysis and cell proliferation owing to their intracellular locali-
zation and kinetic properties. The features of HK2 that may favour 
aerobic  glycolysis  are  mitochondrial  localization  that  allows  the 
consumption of mitochondrially produced ATP to start glycolysis, 
a relatively high affinity for glucose and presence of two catalytically 
active domains that double the rate of glucose-6-phosphate forma-
tion5,6. Although the other pyruvate kinase isozymes are exclusively 
tetrameric enzymes, PKM2 can also switch to a less active dimeric 
form by allosteric regulation in presence of mitogenic signals, lead-
ing to the accumulation of glycolytic intermediates that can be used 
to increase the biomass8. Consistently, HK2 and PKM2 isozymes 
are  reported  to  be  predominantly  expressed  in  highly  malignant 
tumours, and their functional role in promoting tumour progression 
has been demonstrated7,9. Particularly, a relative switch from HK4 
(also named glucokinase) to HK2, and from PKL to PKM2 has been 
observed during progressive stages of liver transformation10–12.
In  liver,  insulin  signalling  through  the  PI3K  pathway  has  a   
fundamental role in the regulation of lipid and glucose metabolism, 
and  pathophysiological  growth.  Gene  deletions  abrogating  PI3K 
activity in mouse liver lead to severe insulin resistance, glucose intol-
erance, increased glucose output and defective lipid neogenesis13. 
Conversely, mutations activating the PI3K pathway, including the 
liver-specific deletion of the phosphatidylinositol (3,4,5)-triphos-
phate-lipid phosphatase and tumor suppressor PTEN (phosphatase 
and  tensin  homologue)  gene,  caused  insulin  hypersensitivity,   
improved glucose tolerance, hepatomegaly, steatosis in young adult 
mice, followed by adenocarcinoma formation since 7 months of 
age14,15. Among the PI3K-dependent effectors, the serine/threonine 
kinase Akt2 is required for the regulation of hepatic glucose output, 
lipid accumulation, and tumorigenesis in PTEN-null livers16–19. In 
this report, we therefore performed genetic epistasis experiments 
to  address  the  impact  of  PI3K/Akt2  activity  on  liver  glycolysis.   
Strikingly, we find that, whereas PTEN deletion causes a general 
upregulation of glycolytic gene expression, Akt2 selectively controls 
HK2  and  PKM2  isozymes.  We  identify  peroxisome  proliferator- 
activated receptor gamma (PPARγ) nuclear hormone receptor as a 
novel transcription factor turning on these specific glycolytic iso-
zymes that are frequently upregulated in pathophysiological growth.
Results
Activation of glycolysis in PTEN-null liver. Consistent with the 
positive role of the PI3K pathway on the cell switch to glycolytic 
metabolism2, PTEN-null mouse livers showed a global upregulation 
of glycolytic enzymes (Fig. 1). The expression of multiple glycolytic 
enzymes that are commonly expressed in liver, including glucokinase 
(GCK),  glucose  phosphate  isomerase  1  (GPI1),  glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), enolase 1 (ENO1), phos-
phoglycerate kinase 1 (PGK1) and L-type pyruvate kinase (PKL)   
was  augmented  at  the  messenger  RNA  and  protein  levels   
(Fig. 1a,b). The increase in expression paralleled increased enzymatic 
activity, while mitochondrial enzymes such as citrate synthase and 
cytochrome c oxydase were not affected (Supplementary Fig. S1). 
These metabolic changes were concomitant with liver triglyceride 
accumulation (steatosis) and hyperplasia, hypoglycaemia and insulin 
hypersensitivity, and preceded the adenocarcinoma formation that 
was observed since 7 months of age14,15 (Supplementary Fig. S2).   
As  Akt2  has  a  crucial  role  mediating  the  action  of  insulin  and 
PI3K  on  hepatic  glucose  homeostasis,  steatosis,  hyperplasia  and 
tumorigenesis16,17,19  (Supplementary  Fig.  S2),  we  addressed  the 
effect of Akt2 deletion on glycolysis of PTEN-null livers. Surprisingly, 
the  upregulation  of  all  the  above  mentioned  glycolytic  enzymes 
was  also  observed  in  AlbCre;PTENf/f;Akt2 − / −   livers  (Fig.  1a,b;   
Supplementary Fig. S1), ruling out an involvement of Akt2 in this 
general activation of glycolysis.
Akt2 controls expression of HK2 and PKM2 in PTEN-null liver. 
Specific glycolytic isozymes, namely HK2 and PKM2 have been 
demonstrated to favour aerobic glycolysis and growth7,20. PKM2 
and HK2 are expressed at low levels in wild-type adult mouse livers. 
As shown in Figure 1b and in Figure 1c, PTEN deletion upregulated 
HK2 and PKM2 mRNA and protein expression. Importantly, Akt2 
deletion was sufficient to reduce by 40–60% the expression of both 
isozymes at 3 months of age, well before tumour onset. In addition, 
Akt2 deletion also blunted mitochondrial levels of HK2 (Fig. 1d), 
which should affect ATP usage towards glycolysis20. Finally, the dif-
ference in HK2 and PKM2 expression in AlbCre;PTENf/f;Akt2 − / −  
livers was accompanied by lower levels of hepatic lactate as com-
pared with AlbCre;PTENf/f (Fig. 1e). Taken together, these data indi-
cate that Akt2 promotes aerobic glycolysis in PTEN-null fatty liver.
Expression of HK2 and PKM2 isozymes promotes liver growth. 
To evaluate the functional outcome of glycolytic isozymes expres-
sion on liver pathophysiology, adenoviral-mediated HK2 overex-
pression was achieved in vivo (Fig. 2a). HK2 overexpression led 
to a 100% increase in liver mass in wild type, and a 135% increase 
in AlbCre;PTENf/f;Akt2 − / −  mice (Fig. 2b). In addition, HK2 pro-
moted  lactate  production,  steatosis  and  hepatocyte  proliferation 
(Fig. 2c,d,e). HK2 also upregulated triglyceride content and lactate 
release after 60 h of overexpression in wild-type primary hepatocyte 
cultures (Supplementary Fig. S3). PKM2 overexpression in vivo in 
wild-type mice caused a 74% increase in liver mass, an effect that 
was comparable to HK2 (Fig. 2b). The combination of both HK2 
and PKM2 further increased liver mass to 134% as compared with 
green fluorescent protein (GFP)-treated control mice. Thus HK2 
and PKM2 overexpression at supraphysiological levels is sufficient 
to cause liver steatosis and growth. In conclusion, a specific pattern ARTICLE     
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of glycolytic isozyme expression correlates with the Akt2-depend-
ent  steatosis,  hyperplasia  and  oncogenic  potential  of  PTEN-null 
liver cells.
Akt2  controls  PPARγ  activity  in  PTEN-null  liver.  Given  the   
distinctive features of PKM2 and HK2 isozymes in regulating cell 
metabolism,  we  set  out  to  determine  the  transcription  factor(s) 
responsible for their selective Akt2-dependent regulation in PTEN-
null  hepatocytes.  We  initially  considered  the  involvement  of  c-
Myc and HIF1α transcription factors, two potent stimulators of   
glycolytic gene transcription4. Consistently, adenoviral transduc-
tion of c-Myc and HIF1α in primary hepatocytes increased PKM2 
and HK2 expression in addition to other glycolytic enzymes such as 
GAPDH, PGK1, ENO1 as well as LDHA, a known non-glycolytic 
target of both factors (Supplementary Fig. S4a). However, we failed 
to reveal a significant regulation of c-Myc and HIF1α expression   
at  the  level  of  mRNA,  total  protein  and  nuclear  protein  in  the   
wild  type,  AlbCre;PTENf/f  and  AlbCre;PTENf/f;Akt2 − / −   livers   
(Supplementary Fig. S4b,c,d). Furthermore, the HIF1α- and c-Myc-
target genes GAPDH, PGK1, ENO1, were not regulated in an Akt2-
dependent manner in livers (Fig. 1). These observations would be 
consistent  with  extra  mechanisms  downstream  of  Akt2  control-
ling PKM2 and HK2 expression. We noticed that fat storing tissues 
also contained abundant amount of PKM2 and HK2. This was the 
case for the epididymal adipose tissues in wild-type mice (Fig. 3a), 
and for steatotic livers in AlbCre;PTENf/f mice (Fig. 1). PPARγ is a 
master regulator of adipogenesis and fat storage21. In liver, PPARγ 
levels  are  increased  during  steatosis  induced  by  high  fat  diet22,   
leptin deficiency23, or the genetic deletion of PTEN14. Importantly, 
we  found  that  the  increase  of  PPARγ  mRNA  and  nuclear  protein   
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Figure 1 | Akt2 controls expression of specific glycolytic isozymes in PTEN-null liver. Relative transcript (a) and protein (b) levels of glycolytic enzymes 
in the mouse livers of indicated genotypes. For protein analysis, the ratio to β-actin of the densitometric assay is presented. Data are mean ± s.e.m., n = 3–7 
(P < 0.05 (a) versus WT; (b) versus AlbCre;PTENf/f; 2-tailed, unpaired student’s t test). (c) RT–QPCR for PKm2 and HK2 expression from mice livers of 
indicated genotypes. Data are mean  ± s.e.m., n = 7 (P < 0.05 (a) versus WT; (b) versus AlbCre;PTENf/f; 2-tailed, unpaired student’s t test). (d) Immunoblot 
analysis of HK2 in liver mitochondria extracts from mice of indicated genotypes. The ratio to VDAC of the densitometric assay  ± s.e.m. is presented, 
n = 3–4 (P < 0.05 (a) versus WT; (b) versus AlbCre;PTENf/f; 2-tailed, unpaired student’s t test). (e) Hepatic lactate levels of random-fed mice of indicated 
genotypes. Data are mean  ± s.e.m., n = 5–8 (P < 0.05 (a) versus WT; (b) versus AlbCre;PTENf/f; 2-tailed, unpaired student’s t test). ARTICLE
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levels  in  AlbCre;PTENf/f  livers  was  reduced  by  35%  and  55%,   
respectively, in the AlbCre;PTENf/f;Akt2 − / −  genotype (Fig. 3b,c), 
correlating with the extent of steatosis (Supplementary Fig. S2). 
The  reduction  of  PPARγ  expression  in  AlbCre;PTENf/f;Akt2 − / −  
livers was accompanied by a comparable reduction of FoXo phos-
phorylation (Supplementary Fig. S5a). FoXo transcription factor 
family members were previously shown to be Akt substrates and 
to regulate PPARγ expression in fat tissues24,25. Interestingly, Akt2 
deletion  also  abrogated  expression  of  hepatic  Cyclooxygenase-2 
(Supplementary Fig. S5b), a rate-limiting enzyme in prostaglandin 
synthesis that was previously shown to be upregulated in PTEN-null 
cells26. Although the nature of PPARγ endogenous ligands is still 
under debate, prostaglandins were proposed as natural regulators 
of PPARγ27. Thus, it is possible that Akt2 activity might affect both 
PPARγ expression and activation in liver. Consistently, Akt2 activity 
contributed to control of the mRNA expression of PPARγ targets, 
namely cluster of differentiation 36 (CD36) and cell death-inducing 
DFFA-like effector-C (CIDE-C) (Fig. 3d). Chromatin immunopre-
cipitation from liver extracts using PPARγ antibodies demonstrated 
that the binding of PPARγ to the promoter of CD36 was dependent 
on Akt2 activation (Fig. 3e).
PKM2  and  HK2  are  novel  transcriptional  targets  of  PPAR. 
By  in  silico  analysis,  it  appeared  that  the  promoter  regions  of 
PKM2  and  HK2  genes  also  contained  several  PPAR  response   
elements (PPRE). Namely, for HK2, they were localized at positions   
 − 2,694 bps,   − 1,216 bp,   − 1,162 bp,   − 756 bp,   − 495 bp  and  for 
PKM2  at   − 2580 bp,   − 2108  bp,   − 2086 bp,   − 1,927 bp,   − 1,028 
bp  and   − 235 bp  from  the  transcription  start  site.  Independent   
chromatin  immunoprecipitation  assays  demonstrated  that,  in 
PTEN-deficient livers, PPARγ binding to one PPRE in the promoter 
of PKM2 (at  − 2,580 bp position) and to one PPRE in the promoter 
of HK2 (at  − 495 bp position) was enriched more than tenfold over 
the IgG control immunoprecipitations (Fig. 3e). Importantly, this 
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binding required Akt2 activity as it was reduced in AlbCre;PTENf/f; 
Akt2 − / −  livers. Taken together, these findings indicate that PKM2 
and HK2 are novel and direct targets of PPARγ, consistent with   
their expression in adipose tissue and fatty liver.
Pioglitazone treatment induces growth of PTEN-null liver. Our 
data suggest that PPARγ may promote metabolic adaptations down-
stream of PI3K and Akt2 pathway favouring hepatocyte steatosis 
and proliferation. However, PPARγ in other systems may also pro-
mote cell differentiation and cell-cycle withdrawal28. Intriguingly, 
PTEN expression has been proposed as one of the possible mecha-
nisms by which PPARγ may exert anti-tumoral actions29. Therefore, 
the functional outcome of PPARγ activity on PTEN-negative liver 
growth is difficult to predict and is important to assess, given the 
potential for pharmacological intervention with PPARγ synthetic 
ligands to treat metabolic diseases30. To this end, PPARγ activity 
was modulated in PTEN-null livers. AlbCre;PTENf/f and wild-type 
mice were daily treated for 12 days with the PPARγ agonist pioglita-
zone. This reduced fed glycaemia in both genotypes (Fig. 4a), con-
sistent with the insulin-sensitizing systemic effect of pioglitazone. 
However, pioglitazone promoted a 62% increase in liver/body ratio 
(Fig. 4b), and a threefold increase in BrdU-positive cells (Fig. 4c), 
exclusively in PTEN-null livers, whereas growth was not induced in 
wild-type liver controls in agreement with the low PPARγ expression   
in this genotype. Strikingly, pioglitazone selectively raised the levels 
of PKM2 and HK2 proteins in AlbCre;PTENf/f livers with no effect 
on PKL and GAPDH levels (Fig. 4d).
PPAR overexpression in vivo induces liver growth. To analyse 
the effects of cell-autonomous activation of PPARγ on liver growth, 
wild-type, AlbCre;PTENf/f and AlbCre;PTENf/f;Akt2 − / −  mice were 
in vivo transduced with PPARγ-expressing adenoviral vector that 
has a pronounced tropism for liver. In line with the results of PPARγ 
activation by pharmacological agents, PPARγ overexpression led 
to  a  significant  increase  in  liver/whole  body  ratio  in  wild  type, 
AlbCre;PTENf/f  and  AlbCre;PTENf/f;Akt2 − / −   livers  as  compared 
with control transduced livers (Supplementary Fig. S6a). The effect 
on liver hypertrophy and steatosis was particularly striking in wild 
type and AlbCre;PTENf/f;Akt2 − / −  tissues, that express low levels 
of endogenous PPARγ (Fig. 5a). Induction of PKM2 and HK2 by 
PPARγ expression was comparable to well-established PPARγ target 
such as CD36 (Fig. 5b). The massive and selective upregulation of 
PKM2 and HK2 over other glycolytic enzymes was confirmed at 
the level of both mRNA and protein (Fig. 5b,c). PKM1 and PKM2 
isoforms are transcribed from the same PKM locus and arise from 
alternative splicing of PKM pre-mRNA leading to inclusion of either 
exon 9 in the PKM1 mature mRNA, or exon 10 in PKM2 (ref. 31). 
Despite their similarities, the effects on aerobic glycolysis and cancer   
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progression are mainly ascribed to PKM2 rather than PKM1 (ref. 7).   
In PPARγ-transduced livers, the transcription of PKM gene was 
upregulated, leading to increased levels of both PKM1 and PKM2 
mRNAs (Fig. 5b). Although the formation of both PKM splice vari-
ants was detected, PKM2 mRNA was more abundant than PKM1 
(Supplementary  Fig.  S6b).  Taken  together,  our  findings  indicate 
that PPARγ acts in vivo on PKM and HK2 gene transcription, and 
that hepatocytes are competent for PKM2 production. To address 
whether glycolysis may concur to the growth-promoting action of 
PPARγ in liver, PPARγ-transduced wild-type mice were treated with 
the glycolytic inhibitor 3-bromopyruvate (3-BrPA)32. 3-BrPA inhib-
ited PPARγ-induced liver growth because of effects on hepatocyte 
proliferation and steatosis (Fig. 5d,e,f).
The liver-cell type expressing PKM2 after PPARγ expression was 
determined by immunostaining as the hepatocytes (Fig. 5g), rul-
ing out the contribution of other cell types to the observed effects   
on  PKM2  expression.  It  was  also  independently  confirmed  by   
modulating PPARγ levels in primary hepatocyte cultures by adeno-
viral transduction, where increasing doses of PPARγ upregulated 
HK2 and PKM2 mRNA and protein levels (Fig. 5h and i). PPARγ 
overexpression had similar effects on the well-established targets 
CD36 and aP2, whereas the levels of other glycolytic enzymes such 
as GAPDH and PGK1 remained constant. Conversely, overexpres-
sion of PPARα was not able to stimulate HK2 and PKM2 mRNA 
levels in primary hepatocytes (Supplementary Fig. S7a). Moreover,   
PPARα  and  PPARβ  expression  was  not  regulated  by  Akt2  in   
livers (Supplementary Fig. S7b). Altogether, our data suggest a cell-
autonomous regulation of HK2 and PKM2 specifically by the γ type 
of PPARs.
Strikingly, the AlbCre;PTENf/f;Akt2 − / −  livers showed pathologi-
cal signs 2 weeks after adeno-PPARγ transduction, including bile 
duct  hyperplasia,  hepatic  lobule  disorganization,  and  ballooning 
hepatocytes (Fig. 5g). Thus, PPARγ orchestrates a gene-expression 
program downstream the PI3K/Akt2 pathway, favouring aerobic 
glycolysis, lipogenesis and pathophysiological growth.
Discussion
Although the role of c-Myc and HIF-1α in general regulation of   
glycolytic enzyme expression is well documented, our understanding   
of molecular mechanisms selectively controlling specific glycolytic 
enzymes is limited. Regulation of HK2 and PKM2 isozymes is espe-
cially interesting, owing to their function in aerobic glycolysis and 
growth. Here we provide evidence that PPARγ has an important role 
in HK2 and PKM2 glycolytic isozyme gene trascription in PTEN-
null fatty liver. We propose that these novel targets, in addition to 
other well-established target genes, concur to the growth and meta-
bolic adaptation of liver to nutrition, insulin, PI3K, Akt2 and PPARγ 
signalling: aerobic glycolysis, steatosis and hepatomegaly (Fig. 5j).
Intense  efforts  have  been  made  to  evaluate  whether  therapy 
with insulin-sensitizing agents, and PPARγ agonists could be ben-
eficial against steatosis-associated human liver diseases, though the   
outcome is not conclusive yet30. The rationale behind these clinical 
trials is that PPARγ agonists should alleviate liver steatosis, promot-
ing lipid accumulation in adipose tissue and suppressing hepatic 
inflammation. This strategy may be appropriate when the origin of 
liver steatosis is environmental, owing to nutritional habits. However, 
liver steatosis and hepatic PPARγ expression may arise from genetic 
insults, as observed when PTEN is deleted and Akt2 upregulated in 
hepatocytes. In these cases, we show that PPARγ activation is detri-
mental, leading to massive steatosis and hepatocyte proliferation.
Regulation of HK2 and PKM2 by hepatic PPARγ is observed well 
before tumour onset, which in PTEN-deficient livers appears since   
7 months of age. It is tempting to speculate that these effects may be   
causally involved in the well-established correlation between liver 
steatosis and increased cancer risk. Whereas PPARγ may act as a 
tumour suppressor in colon, breast and prostate cancers33,34, PPARγ 
activation promotes polyp formation in colon cells carrying muta-
tions in the APC gene35–37. Interestingly, in liver, histone deacety-
lase  3  (Hdac3)  and  nuclear  hormone  co-repressor  (N-CoR)  are 
recruited by several nuclear hormone receptors, including PPARγ, 
to  regulate  transcription  in  the  absence  of  the  ligand.  Loss-of- 
function  mutations  in  these  transcriptional  repressors  promote 
steatosis and pathological liver growth culminating in cancer in 
mice and humans38,39. These studies in combination with our data 
suggest a functional PPARγ/Hdac3/N-CoR complex in the regula-
tion of liver metabolism, which may have important implications in 
tumorigenesis.
Methods
Animal experiments. Generation of AlbCre;PTENf/f and Akt2 − / −  mice has been 
previously described14,16. Mice were maintained at 22 °C with a 12-h-dark/12-h-
light cycle and had free access to food. All animal studies were approved by the 
Direction Départementale des Services Vétérinaires, Préfecture de Police, Paris, 
France (authorization number 75-1313). Pioglitazone was diluted in 0.5%  
carboxymethyl cellulose and was administered at 30 mg kg − 1 dose by daily gavage 
for 12 days. Group of wild-type mice transduced with PPARγ adenovirus were 
treated with 4 mg kg − 1 3-BrPA (Sigma) freshly prepared in PBS and adjusted to 
pH7.4. The drug was injected intraperitoneally every day for 7 days. The first  
injection was 12 h after transduction with adenovirus.
Adenoviruses. Recombinant adenovirus expressing untagged full-length human 
PPARγ2 was a generous gift from Renaud Dentin (Institut Cochin, INSERM 
U1016, UMR8104). Recombinant adenovirus expressing c-Myc was a generous gift 
from Heiko Hermeking (Institute of Pathology Ludwig-Maximilians-University 
Munich)40. Recombinant adenovirus expressing HIF-1αCA5 mutant was a  
generous gift from Gregg L. Semenza (The Johns Hopkins University School of 
Medicine)41. Recombinant adenovirus expressing untagged full-length mouse 
PPARα was described previously42. Recombinant adenovirus expressing V5-tagged 
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full-length human HK2 was custom-generated at GeneCust. Recombinant  
adenovirus expressing untagged human PKM2 was acquired from Excellgen. 
Viruses were generated through homologous recombination between a linearized 
transfer vector pAD-Track and the adenoviral backbone vector pAD-Easy. Viruses 
were purified by the CsCl method and dialysed against PBS buffer containing 7% 
glycerol. For in vivo transduction, 109 of adenoviral infectious particles were  
diluted in 0.9%NaCl and administered retro-orbitally, using 26G needle in total 
volume of 100 µl per mouse, and mice were killed 7 or 14 days postinfection. 
Adenovirus coding for GFP was used as a control in all experiments.
Metabolic studies in mice. At 3 months of age, a glucose tolerance test was 
performed in mice after an overnight fasting (14 h). Mice were intraperitoneally 
injected with 2 g kg − 1 glucose, and blood was collected from the tail vein for 
determination of glucose levels at 0, 15, 30, 45 and 100 min by Glucotrend gluco-
meter (Roche Diagnostics). Insulin tolerance test was performed at 3 months of 
age. Overnight-fasted mice were intraperitoneally injected with 1 U kg − 1 insulin 
(Actrapid), and the glucose concentration in whole blood from the tail vein was 
measured at 0, 15, 30 and 60 min. Fasting insulin levels were measured by ELISA 
assay (Crystal chem).
Immunohistochemistry and morphometric analysis. Liver tissue was fixed over-
night in phosphate-buffered 10% formalin and embedded in paraffin, sectioned in 
4 µm, and stained with eosin/hematoxylin. Immunohistochemistry was performed 
using anti-BrdU antibody (Roche), anti-β-catenin (Calbiochem) and anti-PKM2xp 
(Cell Signalling Technology) antibodies. For 5-bromo-2′deoxyuridine (BrdU) 
incorporation, mice were fed with BrdU (3 mg ml − 1, Sigma-Aldrich) dissolved 
in drinking water for either for 5 days (PIO treatment) or last 24 h (adenoviral 
transduction) before killed. The results were expressed as the ratio of BrdU-positive 
nuclei and total number of nuclei in at least 10 areas of 33,500 µm2 for anti-BrdU 
staining analysed.
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Subcellular fractionation and western blot. Mitochondria were isolated as previ-
ously described43. Briefly, 50–100 mg of snap-frozen liver tissue was homogenized 
in IBc buffer complemented with complete protease inhibitors (Roche). After 
centrifugation at 600 g for 10 min, the supernatant containing the mitochondria 
was centrifugated at 7,000g for 10 min. The pellet of mitochondria was washed 
three times with IBc buffer and, after the final centrifugation, the mitochondria 
were lysed in extraction buffer (20 mM Tris–HCl (pH 8,0), 5% glycerol, 138 mM 
NaCl, 2,7 mM KCl, 1% NP-40, 20 mM NaF, 5 mM EDTA, 1 mM DTT) comple-
mented with complete protease inhibitors (Roche). Nuclear extracts were prepared 
using NE-PER Kit (Pierce), according to manufacturer’s recommendations, using 
50–100 mg of snap-frozen liver tissue as a starting material. Total protein extracts 
were prepared as described before44. Proteins were resolved by SDS–PAGE,  
transferred to polyvinylidene difluoride membrane and incubated with anti-phospho  
Akt (Ser473), anti-aP2, anti-PKM2, anti-HK2, anti-Akt, anti-c-Myc, anti-Lamin 
A/C, anti-phosphoFoXo1/3a (Thr24/32), anti-FoXo3a, anti-phosphoGSK3β (Ser9), 
anti-GSK3β (Cell Signalling), anti-PKL (a generous gift of Benoit Viollet, Cochin 
Institut, Paris), anti-tubulin and anti-β-actin (Sigma), anti-VDAC and anti-CIDE-C 
(Millipore), anti-HK2, anti-TATABP, anti-PPARγ and anti-enolase (Santa Cruz), 
anti-GAPDH and anti-V5 (Abcam), anti-HIF1α (Novus) antibodies.
Hepatic metabolites analysis. TG levels were determined using Triglycerides FS 
Kit (Diasys) according to the manufacturer’s instructions. 50–100 mg of powdered 
liver tissue or pelleted primary hepatocytes were used for acetone extraction. Lac-
tate concentrations were assayed in liver extracts of random-fed mice as described 
previously45. Briefly, metabolites were extracted in 9% perchloric acid from clamp-
frozen liver tissues, neutralized using potassium hydroxide, and assayed using a 
spectrophotometric enzymatic procedure. Lactate levels after adenovirus-mediated 
HK2 overexpression were determined using Lactate reagent (Trinity Biotech) using 
50–100 mg of liver tissue or cell culture medium supernatants. Liver tissue extracts 
before measurement were filtered using 10 K Amicon Ultra columns (Millipore).
RT–QPCR. Total RNA was isolated from 50–100 mg of snap-frozen liver tissue 
using a RNAeasy Lipid Tissue Midi or Mini Kit (Qiagen). Total RNA from hepato-
cytes was isolated using a RNAeasy Mini Kit (Qiagen). Single-strand complemen-
tary DNA was synthesized from 1 µg of total RNA with random hexamer primers 
and SuperScript II (Invitrogen). Real-time quantitative PCR (RT–QPCR) was 
performed on Taqman instrument (Applied Biosystem) using a SYBR Green PCR 
Master Mix (Applied Biosystem). The relative amounts of the mRNAs studied were 
determined by means of the 2 − ∆∆CT method, with pinin, actin or cyclophilin as 
reference genes and control-treated samples as the invariant controls. Primers used 
for analysis are listed in Supplementary Table S1.
For PKM isoform ratio analysis, 1 microlitre of the complementary DNA was 
amplified using DreamTaq Green PCR Master Mix (Fermentas) in total volume of 
50 microlitres. Five microlitres of PCR product was digested by FastDigest EcoNI 
(Fermentas) and the products analysed on agarose gel. An EcoNI site is present in 
exon 9 of mouse PKM1, whereas it is absent in exon 10 of PKM2. Primers used for 
amplification of PKM isoform identification are shown in Supplementary Table S2.
Chromatin immunoprecipitation. Random-fed mice were used for experiment 
with two mice of the same genotype used for preparation in each sample for each 
independent experiment. Chromatin was prepared from freshly dissected liver, 
as previously described46,47. Chromatin was sonicated in SBAR buffer (50 mM 
HEPES, 140 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% sodium deoxycholate and 
0.1% SDS with complete protease inhibitors (Roche) and incubated with antibody 
to PPARγ (Santa Cruz, sc-7196) or IgG as control. Next, immunocomplexes were 
recovered with Protein A sepharose beads (Amersham). After washing, DNA– 
protein complexes were eluted and cross-linking was reversed by heating the 
samples at 65 °C for 16 h. DNA was then purified using Qiagen PCR purification 
kit. Real-time quantitative PCR (RT–QPCR) was performed using a Taqman in-
strument (Applied Biosystem) according to the manufacturer’s instructions, using 
a SYBR Green PCR Master Mix (Applied Biosystem). The relative amounts of the 
immunoprecipitated DNA were determined by means of the 2 − ∆CT method, with 
input DNA values for each sample as the control. The enrichment over IgG control 
of more than tenfold was considered as a cutoff. The results are presented as  
average of fold induction over wild type (WT) for the PPREs confirmed in inde-
pendent experiments. The location of putative PPREs within promoter region of 
PKM2 and HK2 genes was determined using MatInspector software (Genomatix) 
and 3 kb fragment of DNA sequence upstream the transcription start. Numer-
ous potential PPREs were located upstream first exon of HK2 and PKM2 genes: 
HK2:  − 2,694 bp;  − 1,216 bp;  − 1,162 bp;  − 756 bp;  − 495 bp; PKM2:  − 2,580 bp;  
 − 2,108 bp;  − 2,086 bp;  − 1,927 bp;  − 1,028 bp;  − 235 bp. Confirmed PPREs for 
PKM2 and HK2 promoters are PKM2:  − 2,580 bp; HK2:  − 495 bp. The primer  
pairs flanking putative PPREs used for amplification have been designed using 
PrimerBlast software and are listed in Supplementary Table S3.
Hepatocyte culture. Primary hepatocytes were isolated from wild-type C57BL/6J 
mice by collagenase perfusion method as described previously44. 4×105 cells were 
plated in 6-well plates in William’s medium (Invitrogen) supplemented by 20% 
FBS, INS (4 µg ml − 1), 10 units ml − 1 penicillin, 10 g ml − 1 streptomycin, and 25 nM 
dexamethasone (Sigma). After attachment, cells were transduced with adenoviruses   
expressing GFP, PPARα, PPARγ2, c-Myc or HIF-1αCA5 in serum-free William’s 
medium for 2 h in 5-50 MOI dose as indicated. Subsequently, medium was changed 
and cells were maintained in serum-free William’s medium complemented with 
INS and dexametasone. 
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